Tourmaline Bio shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a $50 price target.
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Tourmaline Bio with a Buy rating and a price target of $50. This has led to an increase in the trading of Tourmaline Bio shares.
October 31, 2023 | 6:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tourmaline Bio's stock is trading higher following Guggenheim's initiation of coverage with a Buy rating and a $50 price target.
The initiation of coverage by a major financial institution like Guggenheim often brings a stock into focus for investors. The Buy rating and the $50 price target indicate a positive outlook for the stock, which can lead to increased trading and potentially a higher stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100